On The Media

Pfizer announced Monday that its coronavirus vaccine demonstrated more than 90% effectiveness and no serious bad reactions in trial results — an outcome that should enable the company to obtain an emergency authorization soon. Between the vaccine and the unveiling, also on Monday, of a Biden-led coronavirus task force, it seemed like the rare pandemic-era day in which the good news could compete with the tragic. But Pulitzer Prize–winning science writer Laurie Garrett wrote this week in Foreign Policy that even if this vaccine works as advertised, there are still plenty of reasons to worry about much good it can do. In this podcast extra, Garrett tells Brooke about what she views as caveats to the potential breakthrough.  CORRECTION: This podcast contains an error concerning the timing of testing after the second dose of Pfizer's coronavirus vaccine candidate. According to a protocol released by Pfizer, Phase 3 study participants were tested for coronavirus "at least 7 days after receipt of the second dose,"